JP2006517591A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006517591A5 JP2006517591A5 JP2006503494A JP2006503494A JP2006517591A5 JP 2006517591 A5 JP2006517591 A5 JP 2006517591A5 JP 2006503494 A JP2006503494 A JP 2006503494A JP 2006503494 A JP2006503494 A JP 2006503494A JP 2006517591 A5 JP2006517591 A5 JP 2006517591A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- halo
- group
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 17
- 125000003118 aryl group Chemical group 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 125000001072 heteroaryl group Chemical group 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- -1 alkyl luma Chemical compound 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 125000002950 monocyclic group Chemical group 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 5
- 230000001404 mediated effect Effects 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 3
- 125000002541 furyl group Chemical group 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 102000036530 EDG receptors Human genes 0.000 claims 2
- 108091007263 EDG receptors Proteins 0.000 claims 2
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 claims 2
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 241000023320 Luma <angiosperm> Species 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000004075 alteration Effects 0.000 claims 1
- 230000001548 androgenic effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 125000005730 thiophenylene group Chemical group 0.000 claims 1
- 125000000732 arylene group Chemical group 0.000 description 3
- 125000001475 halogen functional group Chemical group 0.000 description 3
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 description 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004957 naphthylene group Chemical group 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44664803P | 2003-02-11 | 2003-02-11 | |
| US46480903P | 2003-04-21 | 2003-04-21 | |
| US47201203P | 2003-05-19 | 2003-05-19 | |
| PCT/US2004/004006 WO2004071442A2 (en) | 2003-02-11 | 2004-02-11 | Novel bicyclic compounds and compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006517591A JP2006517591A (ja) | 2006-07-27 |
| JP2006517591A5 true JP2006517591A5 (enExample) | 2010-04-22 |
| JP4505449B2 JP4505449B2 (ja) | 2010-07-21 |
Family
ID=32872761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006503494A Expired - Fee Related JP4505449B2 (ja) | 2003-02-11 | 2004-02-11 | 新規二環式化合物および組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7256206B2 (enExample) |
| EP (1) | EP1594508B1 (enExample) |
| JP (1) | JP4505449B2 (enExample) |
| AU (1) | AU2004210697B2 (enExample) |
| BR (1) | BRPI0407401A (enExample) |
| CA (1) | CA2515638A1 (enExample) |
| ES (1) | ES2393551T3 (enExample) |
| MX (1) | MXPA05008531A (enExample) |
| PL (1) | PL378134A1 (enExample) |
| WO (1) | WO2004071442A2 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1602660T3 (da) * | 2003-02-18 | 2011-05-23 | Kyorin Seiyaku Kk | Aminophosphonsyrederivater, additionssalte deraf og S1P-receptormodulatorer |
| MY150088A (en) * | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
| US7718704B2 (en) * | 2004-02-24 | 2010-05-18 | Irm Llc | Immunosuppressant compounds and compositions |
| CN101905023B (zh) * | 2004-07-16 | 2012-07-11 | 杏林制药株式会社 | 有效的医药使用方法及与副作用发生的防御相关的方法 |
| PL1806338T3 (pl) * | 2004-10-12 | 2016-07-29 | Kyorin Seiyaku Kk | Sposób wytwarzania chlorowodorku 2-amino-2-[2-[4-(3-benzyloksyfenylotio)-2-chlorofenyio]etylo]-1,3-propanodioiu i jego hydratów oraz produkty pośrednie w ich wytwarzaniu |
| CA2583681A1 (en) * | 2004-10-22 | 2006-05-04 | Merck & Co., Inc. | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists |
| CA2591399C (en) * | 2004-12-13 | 2014-05-20 | Ono Pharmaceutical Co., Ltd. | Aminocarboxylic acid derivative and medicinal use thereof |
| SI1932522T1 (sl) * | 2005-10-07 | 2012-08-31 | Kyorin Seiyaku Kk | Terapevtsko sredstvo za jetrno bolezen, ki vsebuje 2-amino-1,3- propandiolni derivat kot aktivno sestavino |
| TWI389683B (zh) * | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
| US20070191371A1 (en) * | 2006-02-14 | 2007-08-16 | Kalypsys, Inc. | Heterocyclic modulators of ppar |
| US8097644B2 (en) | 2006-03-28 | 2012-01-17 | Allergan, Inc. | Indole compounds having sphingosine-1-phosphate (S1P) receptor antagonist |
| RU2430925C2 (ru) | 2006-08-08 | 2011-10-10 | Киорин Фармасьютикал Ко., Лтд. | Производное аминофосфата и модулятор рецептора s1p, содержащий его в качестве активного ингредиента |
| CA2659599C (en) | 2006-08-08 | 2014-06-17 | Kyorin Pharmaceutical Co., Ltd. | Amino alcohol derivative and immunosuppressive agent having same as an active ingredient |
| US8524917B2 (en) | 2007-01-11 | 2013-09-03 | Allergan, Inc. | 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity |
| BRPI0817397A2 (pt) | 2007-09-24 | 2015-04-07 | Allergan Inc | Compostos indol contendo grupos arila ou heteroarila com atividade biológica do receptor de esfingosina-1-fosfato (sip) |
| WO2009085847A1 (en) | 2008-01-03 | 2009-07-09 | Allergan, Inc. | Tetrahydroindoles having sphingosine-1-phosphate receptor activity |
| JP5452237B2 (ja) | 2008-02-07 | 2014-03-26 | 杏林製薬株式会社 | アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤 |
| CA2723775A1 (en) | 2008-05-08 | 2009-11-12 | Allergan, Inc. | Therapeutically useful substituted 1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinoline compounds |
| US8143291B2 (en) | 2008-05-09 | 2012-03-27 | Allergan, Inc. | Indole compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (S1P) receptor biological activity |
| JP2011523646A (ja) | 2008-05-21 | 2011-08-18 | アリアド・ファーマシューティカルズ・インコーポレイテッド | キナーゼ阻害剤としてのリン誘導体 |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| CN104311472B9 (zh) | 2008-07-23 | 2020-03-17 | 艾尼纳制药公司 | 经取代的1,2,3,4-四氢环戊并[b]吲哚-3-基乙酸衍生物 |
| PL2342205T4 (pl) | 2008-08-27 | 2016-12-30 | Podstawione tricykliczne pochodne kwasowe jako antagoniści receptora S1P1 użyteczni w leczeniu zaburzeń autoimmunologicznych i zapalnych | |
| US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
| EP2528894A1 (en) | 2010-01-27 | 2012-12-05 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| CN105503882B (zh) | 2010-03-03 | 2019-07-05 | 艾尼纳制药公司 | 制备s1p1受体调节剂及其晶体形式的方法 |
| JP5735634B2 (ja) | 2010-04-23 | 2015-06-17 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | スフィンゴシン−１−リン酸受容体１アゴニストとしての４−（５−イソオキサゾリルまたは５−ピラゾリル−１，２，４−オキサジアゾール−３−イル）−マンデル酸アミド化合物 |
| WO2012040532A1 (en) | 2010-09-24 | 2012-03-29 | Bristol-Myers Squibb Company | Substituted oxadiazole compounds and their use as s1p1 agonists |
| AU2012250517B2 (en) | 2011-05-04 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物 |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| CA3002540C (en) | 2015-01-06 | 2023-11-07 | Arena Pharmaceuticals, Inc. | Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor |
| JP6838744B2 (ja) | 2015-06-22 | 2021-03-03 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩 |
| CN110520124A (zh) | 2017-02-16 | 2019-11-29 | 艾尼纳制药公司 | 用于治疗原发性胆汁性胆管炎的化合物和方法 |
| KR20190113955A (ko) | 2017-02-16 | 2019-10-08 | 아레나 파마슈티칼스, 인크. | 장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법 |
| JP7397011B2 (ja) | 2018-06-06 | 2023-12-12 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｓ１ｐ１受容体に関連する状態を治療する方法 |
| EP3847158B1 (en) | 2018-09-06 | 2026-06-24 | Arena Pharmaceuticals, Inc. | Compounds useful in the treatment of autoimmune and inflammatory disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EE9600121A (et) * | 1994-03-31 | 1997-04-15 | Amgen Inc. | Megakarüotsüütide kasvu ja diferentseerumist stimuleerivad kompositsioonid ja meetodid |
| MXPA03008755A (es) * | 2001-03-26 | 2004-02-18 | Novartis Ag | Derivados de 2-amino-propanol. |
| WO2003099192A2 (en) * | 2002-05-27 | 2003-12-04 | Novartis Ag | Bis-aromatic alkanols |
| CN100516024C (zh) * | 2002-09-13 | 2009-07-22 | 诺瓦提斯公司 | 氨基-丙醇衍生物 |
| JP2004307440A (ja) * | 2003-04-10 | 2004-11-04 | Kyorin Pharmaceut Co Ltd | ２−アミノ‐１，３‐プロパンジオール誘導体とその付加塩 |
| AU2004234067B2 (en) * | 2003-04-30 | 2008-02-28 | Novartis Ag | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators |
-
2004
- 2004-02-11 MX MXPA05008531A patent/MXPA05008531A/es active IP Right Grant
- 2004-02-11 EP EP04710227A patent/EP1594508B1/en not_active Expired - Lifetime
- 2004-02-11 WO PCT/US2004/004006 patent/WO2004071442A2/en not_active Ceased
- 2004-02-11 AU AU2004210697A patent/AU2004210697B2/en not_active Ceased
- 2004-02-11 US US10/776,946 patent/US7256206B2/en not_active Expired - Fee Related
- 2004-02-11 ES ES04710227T patent/ES2393551T3/es not_active Expired - Lifetime
- 2004-02-11 JP JP2006503494A patent/JP4505449B2/ja not_active Expired - Fee Related
- 2004-02-11 PL PL378134A patent/PL378134A1/pl not_active Application Discontinuation
- 2004-02-11 CA CA002515638A patent/CA2515638A1/en not_active Abandoned
- 2004-02-11 BR BRPI0407401-7A patent/BRPI0407401A/pt not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6496823B2 (ja) | 新規置換インダゾール、その製造方法、前記新規置換インダゾールを含む医薬製剤、および薬剤を製造するための前記新規置換インダゾールの使用 | |
| JP7033079B2 (ja) | 芳香族スルホンアミド誘導体 | |
| ES2934181T3 (es) | Inhibidores de la interacción MDM2-P53, basados en isoindolinona, con actividad antineoplásica | |
| KR20170081204A (ko) | 제약 화합물 | |
| JP2009526761A5 (enExample) | ||
| JP2019031560A5 (enExample) | ||
| JP2007538024A5 (enExample) | ||
| JP2009523724A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2008513496A5 (enExample) | ||
| JP2008513516A5 (enExample) | ||
| JP2019515884A5 (enExample) | ||
| JP2010539171A (ja) | 高血圧を処置するためのチアゾリジンジオン類似体 | |
| GEP20115213B (en) | Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists | |
| US11401278B2 (en) | Macrocyclic indole derivatives | |
| JP2006524669A5 (enExample) | ||
| JP2018529745A5 (enExample) | ||
| JP2009539943A5 (enExample) | ||
| CZ243093A3 (en) | Benzofuran derivatives, process of their preparation and pharmaceutical preparations in which they are comprised | |
| JP2021501178A (ja) | 虚血性脳卒中の治療のための芳香族スルホンアミド誘導体 | |
| JP2007523909A5 (enExample) | ||
| CN107108554B (zh) | 作为midh1抑制剂用于治疗肿瘤的1-环己基-2-苯基氨基苯并咪唑 | |
| JP2025512995A (ja) | カンナビノイド受容体１アンタゴニスト／インバースアゴニスト及びその使用 | |
| JP2019520344A5 (enExample) | ||
| JP2007537287A5 (enExample) |